Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 235

Similar articles for PubMed (Select 18363521)

1.

Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.

Giannoukakis N.

Expert Opin Investig Drugs. 2008 Apr;17(4):575-81. doi: 10.1517/13543784.17.4.575 . Review.

PMID:
18363521
2.

Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.

Giannoukakis N.

Curr Opin Investig Drugs. 2006 Oct;7(10):916-23. Review.

PMID:
17086937
3.
4.

Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.

Matsumoto T, Ono Y, Kuromiya A, Toyosawa K, Ueda Y, Bril V.

J Pharmacol Sci. 2008 Jul;107(3):340-8. Epub 2008 Jul 8.

5.

Evaluation of ranirestat for the treatment of diabetic neuropathy.

Giannoukakis N.

Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):1051-9. doi: 10.1517/17425255.2014.916277. Epub 2014 Apr 30. Review.

PMID:
24785785
6.

Aldose reductase and its inhibition in the control of diabetic complications.

Narayanan S.

Ann Clin Lab Sci. 1993 Mar-Apr;23(2):148-58. Review.

PMID:
8457142
7.
8.

Aldose reductase inhibitors.

Kirchain WR, Rendell MS.

Pharmacotherapy. 1990;10(5):326-36. Review.

PMID:
2122421
9.

Ranirestat for the management of diabetic sensorimotor polyneuropathy.

Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group.

Diabetes Care. 2009 Jul;32(7):1256-60. doi: 10.2337/dc08-2110. Epub 2009 Apr 14.

10.

Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.

Saraswat M, Muthenna P, Suryanarayana P, Petrash JM, Reddy GB.

Asia Pac J Clin Nutr. 2008;17(4):558-65.

11.

Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.

Schemmel KE, Padiyara RS, D'Souza JJ.

J Diabetes Complications. 2010 Sep-Oct;24(5):354-60. doi: 10.1016/j.jdiacomp.2009.07.005. Epub 2009 Sep 11. Review.

PMID:
19748287
12.

The role of aldose reductase inhibitors in diabetic complications: recent trends.

Kaul CL, Ramarao P.

Methods Find Exp Clin Pharmacol. 2001 Oct;23(8):465-75. Review.

PMID:
11838322
13.

Clinical potential of aldose reductase inhibitors in diabetic neuropathy.

Hamada Y, Nakamura J.

Treat Endocrinol. 2004;3(4):245-55. Review.

PMID:
16026107
14.

Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.

Matsumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V.

J Pharmacol Sci. 2009 Feb;109(2):203-10. Epub 2009 Feb 10.

15.

Discoveries in research on diabetic keratopathy.

Cisarik-Fredenburg P.

Optometry. 2001 Nov;72(11):691-704. Review.

PMID:
12363257
16.

Aldose reductase / polyol inhibitors for diabetic retinopathy.

Obrosova IG, Kador PF.

Curr Pharm Biotechnol. 2011 Mar 1;12(3):373-85. Review.

PMID:
20939801
17.

Potential use of aldose reductase inhibitors to prevent diabetic complications.

Zenon GJ 3rd, Abobo CV, Carter BL, Ball DW.

Clin Pharm. 1990 Jun;9(6):446-57. Review.

PMID:
2114249
18.

Aldose reductase inhibitors and diabetic complications.

Raskin P, Rosenstock J.

Am J Med. 1987 Aug;83(2):298-306. Review. No abstract available.

PMID:
3113248
19.

Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors.

Madhu SV, Verma NP, Goel A, Kapoor VK.

J Assoc Physicians India. 1992 Oct;40(10):679-81. Review. No abstract available.

PMID:
1307356
20.

Recent studies of aldose reductase enzyme inhibition for diabetic complications.

Suzen S, Buyukbingol E.

Curr Med Chem. 2003 Aug;10(15):1329-52. Review.

PMID:
12871133
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk